To study polypoidal lesions and branching choroidal vascular networks in eyes with polypoidal choroidal vasculopathy by optical coherence tomography (OCT)–based angiography (OCTA).
In the observational cross-sectional study, patients with polypoidal choroidal vasculopathy, as diagnosed by indocyanine green angiography, underwent OCTA.
Thirty-two eyes of 31 patients with an age of 61.1 ± 7.6 years were included. Branching choroidal vascular networks were detected by indocyanine green angiography and OCTA in 25 of 32 (78 ± 73%) and in 30 of 32 (94 ± 4%) eyes, respectively, with a marginally significant difference (P = 0.06) in the detection rate between both techniques. A total of 72 polyps (area, 0.06 ± 0.06 mm2; range, 0.01–0.27 mm2) were detected by indocyanine green angiography, and they were consistently present on the OCTA images. By moving the reference level in the OCT angiograms to the corresponding layer, the polypoidal lesions showed cluster-like structures in 53 of 72 polypoidal lesions (74%). In 60 of the 72 polypoidal lesions (83%), cluster-like structures were detected in the en face structural OCT images at the reference plane of the OCTA images. On the cross-sectional OCT images, some internal channels of flow were seen in 50 of the 72 polypoidal lesions (69%). Larger size of the polypoidal lesions was associated with a higher prevalence of cluster-like structures on the OCTA images, some internal channels of flow on the en face structural images, and clustered vascular structures on the cross-sectional OCT images.
In conclusion, OCTA is a useful technique for the noninvasive detection of branching choroidal vascular networks including visualization of details such as cluster-like structures and flow. In some eyes, OCTA was superior to indocyanine green angiography to detect polypoidal choroidal vasculopathy and to show branching choroidal vascular networks.
Optical coherence tomography –based angiography is a useful technique for the noninvasive detection of branching vascular networks including visualization of details such as cluster-like structures and flow. In some eyes, optical coherence tomography angiography was superior to indocyanine green angiography to detect polypoidal choroidal vasculopathy and to show branching vascular networks.
*Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Ophthalmology and Visual Science Key Lab, Capital Medical University, Beijing, China;
†Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology and Visual Science Key Lab, Beijing, China; and
‡Department of Ophthalmology, Medical Faculty Mannheim of the Ruprecht-Karls-University Heidelberg, Mannheim, Germany.
Reprint requests: Wen Bin Wei, MD, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology and Visual Science Key Laboratory, 1 Dong Jiao Min Xiang, Dong Cheng District, Beijing 100730, China; e-mail: firstname.lastname@example.org
Supported by the Beijing Municipal Administration of Hospitals' Ascent Plan (code: DFL20150201); Science and Technology Project of Beijing Municipal Science and Technology Commission (Z151100001615052), the National Natural Science Foundation of China (Nr.81570891), the Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201307), the National Natural Science Foundation of China (81272981), the Beijing Natural Science Foundation (7151003), and the Advanced Health Care Professionals Development Project of Beijing Municipal Health Bureau (2014-2-003).
J. B. Jonas: Consultant for Mundipharma Co. (Cambridge, United Kingdom); Patent holder with Biocompatibles UK Ltd. (Franham, Surrey, United Kingdom) (Title: Treatment of eye diseases using encapsulated cells encoding and secreting neuroprotective factor and/or anti-angiogenic factor; Patent Number: 20120263794), and Patent application with University of Heidelberg (Heidelberg, Germany) (Title: Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia; European Patent Number: 3 070 101). The remaining authors have no conflicting interests to disclose.
J. B. Jonas and W. B. Wei share the last authorship.